Natural antibodies and complement modulate intimal thickening after arterial injury.
Immune factors are involved in modulating neointimal response to arterial wall injury, but the role of individual immune effectors in this response remains unclear. Using a carotid cuff injury model in mice, we tested the role of immunoglobulin isotypes in modulating intimal thickening by using adoptive transfer of splenocytes from WT mice, or the direct administration of IgG or IgM into immune-deficient Rag-1-/- [Rag-1 knockout (Rag-1KO)] mice. The direct role of complement was also tested by depletion of complement. Splenocytes from WT mice were isolated and adoptively transferred to Rag-1KO mice subjected to carotid cuff arterial injury. Transfer of splenocytes to Rag-1KO mice resulted in increased serum IgM and IgG within 48 h and were comparable to WT levels by 21 days after injury. Splenocyte transfer in Rag-1KO decreased intimal area by 40% compared with Rag-1KO mice without cell transfer. To further differentiate the relative contribution of IgM or IgG in reducing intimal thickening, additional groups of Rag-1KO mice were subjected to injury and given intravenous injections of pooled mouse IgG or IgM. Both IgG and IgM treatment significantly reduced intimal thickening compared with untreated Rag-1KO mice. Immunoglobulin treatments modified serum complement C3 profile and decreased C3 presence in injured arteries. Depletion of C3 using cobra venom factor in Rag-1KO mice significantly decreased intimal thickening. Our results identify the direct role of natural IgG and IgM, and complement in the modulation of neointimal response to arterial injury.
Dimayuga
Paul C
PC
Oppenheimer Atherosclerosis Research Center, Division of Cardiology, Cedars-Sinai Heart Institute, Los Angeles 90048, USA. dimayugap@cshs.org
Cesena
Fernando H Y
FH
Chyu
Kuang-Yuh
KY
Yano
Juliana
J
Amorn
Allen
A
Fishbein
Michael C
MC
Shah
Prediman K
PK
Cercek
Bojan
B
D000818:Animals; D020212:Carotid Artery Injuries / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D003176:Complement C3 / Q000502:physiology*; D004195:Disease Models, Animal; D018398:Homeodomain Proteins / Q000235:genetics / Q000502:physiology; D007107:Immune System / Q000502:physiology; D007154:Immune System Diseases / Q000276:immunology / Q000473:pathology; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000502:physiology* / Q000627:therapeutic use; D007075:Immunoglobulin M / Q000008:administration & dosage / Q000502:physiology* / Q000627:therapeutic use; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D013154:Spleen / Q000473:pathology; D017539:Tunica Intima / Q000276:immunology / Q000473:pathology*
D003176:Complement C3; D018398:Homeodomain Proteins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; C064658:RAG-1 protein